Roy, P. (2026) “Magnitude of Survival Benefit Associated With Tyrosine Kinase Inhibitors in Advanced Thyroid Carcinoma: A Systematic Review and Meta-Analysis Incorporating Updated Long-Term Evidence From SELECT (Lenvatinib) and COSMIC-311 (Cabozantinib) Trials”, World Journal of Oncology, 17(5), pp. 599–613. doi:10.14740/wjon2842.